Low
₹
High
₹
| Previous Close | ₹23.50 |
|---|---|
| Day's Range | ₹22.75 - ₹23.85 |
| Open | ₹23.75 |
| 52 Week Range | ₹20.95 - ₹49.70 |
| Volume | 1,391 |
| Market Cap | ₹0.00 |
| Trade Value ( ₹ in Lacs) | 0.33 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 93.59 |
| TTM EPS (₹) | 0.25 |
| P/E Ratio | 101.80 |
| Book Value(₹) | 1.57 |
| PAT Margin (%) | 2.69 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 8.41 |
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 369.64 | 84.91 |
| Expenses | N/A | N/A |
| PBT | 13.16 | 2.0 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 9.94 | 1.57 |
| Founded | 1993 |
|---|---|
| Managing Director | B Deepak Reddy |
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,66,178.79 | 1,944.65 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,96,095.00 | 7,275.10 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,91,530.43 | 5,048.70 | 3,480.60 - 3,480.60 |
| Apollo Hospitals Enterprise Ltd. | 1,28,516.16 | 8,830.85 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,14,318.19 | 1,378.60 | 1,165.70 - 1,165.70 |
| Zydus Lifesciences Ltd. | 1,12,693.00 | 1,113.30 | 835.50 - 835.50 |
| Lupin Ltd. | 1,10,001.57 | 2,395.80 | 1,836.80 - 1,836.80 |
| Max Healthcare Institute Ltd. | 1,05,274.12 | 1,083.60 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 1,05,068.24 | 2,540.35 | 1,909.70 - 1,909.70 |
| Dr. Reddy's Laboratories Ltd. | 98,742.15 | 1,161.90 | 1,148.40 - 1,148.40 |
No Records Found
Pursuant to Regulation 30 of the Listing Regulations, Sanofi India has informed that Rachid Ayari (DIN:10408699) vide his letter dated 22nd July 2026, had conveyed his decision to step down from his current role as the Whole Time Director, Chief Financial Officer and Key Managerial Personnel of the Company with effect from the close of business hours on 30th September 2026, in view of his transition to another role within the Sanofi group. Accordingly, Rachid Ayari shall cease to be the Whole Time Director, Chief Financial Officer, Key Managerial Personnel and shall also cease to be Senior Management Personnel and member of the Risk Management Committee effective from the close of business hours on 30th September 2026. The Company places on record its sincere appreciation to Rachid Ayari for his valuable contributions, expert guidance, and dedicated assistance provided during his tenure with the Company. The Company is in the process of identifying a suitable candidate for the position of Chief Financial Officer, who will also be designated as a Key Managerial Personnel. The Company will inform the Stock Exchanges of the appointment in due course. The information required in terms of Regulation 30 read with Schedule III of the Listing Regulations and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January 2026 is enclosed as ‘Annexure-I’ and letter received from Rachid Ayari is enclosed as ‘Annexure – II’.
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Dr. Reddy’s Laboratories has informed that it enclosed the link of the audio recordings of the Earnings call for the quarter ended June 30, 2026, conducted on July 22, 2026.
The above information is a part of company’s filings submitted to BSE.
No Records Found
The current share price of Bandaram Pharma Packtech Ltd. is ₹23.50 as of 2026-07-23.
The market capitalisation of Bandaram Pharma Packtech Ltd. is ₹41.93 as of 2026-07-22.
The 1-year return of Bandaram Pharma Packtech Ltd. is -14.50% as of 2025-07-22.
The P/E ratio of Bandaram Pharma Packtech Ltd. is 101.80 as of 2026-07-23.
The 52-week high and low of Bandaram Pharma Packtech Ltd. are ₹49.70 and ₹20.95, respectively, as of 2026-07-23.
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.